ARTELO BIOSCIENCES INC (ARTL)
US04301G5080 - Common Stock
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia
Phase 1 data from the CAReS trial showed an attractive safety profile and promising activity from daily ART27.13 administration with two-thirds of...
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit
SOLANA BEACH, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
ART26.12, the Company’s Lead Clinical Fatty Acid Binding Protein 5 Inhibitor, Continues to Show Positive Preclinical Results in Multiple Pain Studies...
Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
SOLANA BEACH, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program
SOLANA BEACH, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th
SOLANA BEACH, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Artelo Biosciences (NASDAQ:ARTL) just reported results for the second quarter o...
ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q2 2024
ARTL stock results show that Artelo Biosciences beat analyst estimates for earnings per share the second quarter of 2024.
Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
SOLANA BEACH, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor
ART26.12 seeks to address a critical need in painful neuropathies, including chemotherapy-induced peripheral neuropathy for which there is no FDA-approved...
Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium
Multiple studies confirm ART12.11’s superior advantages as a product candidate for the treatment of anxiety related disorders...
Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform
Inhibition of FABP5 Demonstrates Activity in Cancer, Psoriasis, and Anxiety Disorders Results from Several Research Studies Presented at the Annual ICRS...
Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium
SOLANA BEACH, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society
ART26.12 shows efficacy in breast cancer-induced bone pain and diabetic neuropathy...
Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24
ART12.11 demonstrates comparable pharmacokinetics compared to Epidiolex®...
ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q1 2024
ARTL stock results show that Artelo Biosciences beat analyst estimates for earnings per share the first quarter of 2024.
Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
SOLANA BEACH, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th
SOLANA BEACH, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
Provides Further Evidence of Multiple Opportunities for Development of the FABP Inhibitor Platform in Cancer & Other Serious Conditions
Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
SOLANA BEACH, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
ARTL Stock Earnings: Artelo Biosciences Misses EPS for Q4 2023
ARTL stock results show that Artelo Biosciences missed analyst estimates for earnings per share the fourth quarter of 2023.
ARTL Stock Earnings: Artelo Biosciences Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Artelo Biosciences (NASDAQ:ARTL) just reported results for the fourth quarter o...
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
Major achievements in 2023 lay the foundation for key upcoming milestones...
Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge
ART26.12 Preclinical Dermatology Research Presented to the Immuno-dermatology Leadership Team at Johnson & Johnson...
Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
SOLANA BEACH, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12
SOLANA BEACH, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
ART12.11 demonstrated improved bioavailability of CBD in both the fed and fasted states...
Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
$12.9 Million in Cash and Investments as of September 30, 2023;Runway Expected to Reach Meaningful Development Milestones On Track to Submit IND...
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers
SOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023
SOLANA BEACH, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Principal Investigator of Artelo’s CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia
SOLANA BEACH, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th
SOLANA BEACH, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...